Business
Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone // The Motley Fool Australia
The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents.
Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to support cancer patients undertaking chemotherapy or radiotherapy treatment.
Noxopharm share price rockets upon survival benefit results
The company announced today that it would present its latest research findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium later this week.
The research pertains to extending the lives of patients who have late-stage prostate cancer.
Noxopharm’s LuPIN study enrolled a total of 56 patients with metastatic…
-
Business18 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
General23 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Noosa News13 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track
-
Noosa News20 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal